TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Role of Oral Sucrose in Reducing the Pain to Orogastric Tube Insertion in Preterm Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All pre-terms ( \< 37 weeks of gestational age.)~* Within the first 7 days postnatal days (\</=168 hours).~* Clinically stable from respiratory, hemodynamic and metabolic point of view.~* Who have not received any painful stimulus at least 30 minutes prior to the intervention.~* Requiring routine orogastric tube insertion within the first 7 days of life.~* Only the first attempt at putting OGT in controlled NICU environment will be considered~Exclusion Criteria:~The neonates with the following characteristics will be excluded from the study:~* Neonates requiring ventilatory support.~* Neonates requiring oxygen supplementation.~* Having any facial congenital anomalies.~* Having any neurological impairment.~* Receiving opiates or born to mothers receiving opiates.~* New born babies to whom muscle relaxants, sedatives and analgesics have been administered.~* With grade 3 and 4 IVH.~* With major congenital anomalies~* Any history of birth trauma especially involving face or scalp (including cephalhematoma/ subgaleal bleed).~* Face presentation.

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 167 Hours
- Healthy Volunteers: f

Study Arms:
- Sucrose (Type: ACTIVE_COMPARATOR): 1 ml of 24% sucrose was administered 2 minutes before the procedure
- Placebo (Type: PLACEBO_COMPARATOR): Double distilled water

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: School Water Access, Food and Beverage Intake, and Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 4th grade students, students in 4th grade combination classes who speak English or Spanish and who don't have health conditions that preclude intake of water~* School administrators and food service directors at study schools~Exclusion Criteria:~* Students not in the 4th grade or 4th grade combination classes~* Students who do not speak English or Spanish

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Water Access and Promotion - Students (Type: EXPERIMENTAL): Intervention group will receive installation of water stations in high traffic areas, schoolwide promotion, and 4th graders will receive a curricula focused on increasing intake of water.
- Control - Students (Type: NO_INTERVENTION): Participants do not receive an intervention
- School Personnel (Type: NO_INTERVENTION): School administrators and food service managers provide information on school policies and procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have had a diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at least 12 months prior to the first screening procedure.~* Have a PASI score of 12 or greater AND a PGA score of 3 (moderate) or 4 (severe) at Baseline (Day 1).~* Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis (either naïve or history of previous treatment).~Exclusion Criteria:~* Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis, with the exception of nail psoriasis which is allowed.~* Have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium.~* Subjects who cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy (UVB or PUVA) for the study are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo BID (Type: PLACEBO_COMPARATOR): None
- 5mg BID CP-690,550 (Type: EXPERIMENTAL): None
- 10mg BID CP-690,550 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Controlled Pregabalin Trial In Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites.~* Patients must have a score of \>40 mm on the Visual Analog Scale~Exclusion Criteria:~* Patients with any widespread inflammatory musculoskeletal disorders, widespread rheumatic diseases other than fibromyalgia, active infections, or untreated endocrine disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults with Type 1 or 2 diabetes~* Patients must have pain in their lower legs or feet due to painful diabetic neuropathy that has lasted for at least 3 months~Exclusion Criteria:~* Patients must not be in poor or unstable health.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Men \& women ≥ 18 years of age~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1~* Histologically confirmed Stage III (unresectable)/Stage IV melanoma~* Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria~* Objective evidence of disease progression (clinical or radiological) during or after at least 1 (V600 Wildtype) or at least 2 (V600 mutation positive) prior treatment regimens~* Pre-treatment fresh core, excision or punch tumor biopsy~* Archival Formalin-fixed paraffin-embedded (FFPE) tumor material if available~Exclusion Criteria:~* Any treatment in a BMS-936558 (Nivolumab) trial~* Subjects with condition requiring systemic treatment with either corticosteroids (\> 10mg daily prednisone/equivalent) or other immunosuppressive medications within 14 days of study drug administration~* Active, known or suspected autoimmune disease~* Unknown BRAF status~* Active brain metastasis or leptomeningeal metastasis~* Ocular melanoma~* Prior therapy with anti programmed death-1 (anti-PD-1), anti programmed death-ligand 1 (anti-PD-L1) or anti-programmed death-ligand 2 (anti-PD-L2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMS-936558 3 mg/kg (IV) (Type: EXPERIMENTAL): BMS-936558 3 mg/kg solution for injection by intravenous (IV), every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
- Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel) (Type: ACTIVE_COMPARATOR): Dacarbazine: 1000mg/m2, Powder for IV solution, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Carboplatin: Area under the concentration-time curve (AUC) 6, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Paclitaxel: 175 mg/ m2, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Monurol for Treatment of Acute Cystitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non pregnant women in good health with symptoms of acute cystitis for less than 7 days~Exclusion Criteria:~* Pregnant, lactating, or not regularly contracepting~* History of chronic conditions such as diabetes~* Known anatomic abnormalities of the urinary tract~* Use of prophylactic antibiotics~* History of allergy or intolerance to any of the study drugs~* Recent (\> 2 weeks)exposure to oral or parenteral antimicrobial~* History of UTI in previous 1 month

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- TMP/SMX (Type: ACTIVE_COMPARATOR): Sulfamethoxazole-Trimethoprim 800-160 MG Oral Tab; 800mg/160mg BID x 3 days
- Fosfomycin (Type: EXPERIMENTAL): 3g sachet single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients aged 5 to 17 years.~* Written consent / assent.~* Grass pollen-related allergic rhinoconjunctivitis for at least the last two pollen seasons.~* Sensitised to grass pollen (positive SPT and grass pollen-specific IgE values of at least Class 2).~* Total symptom score on the Retrospective RTSS during the previous pollen season of greater than or equal to 12.~Exclusion Criteria:~* Patients who have received any desensitisation treatment for grass pollen.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 300 IR (Type: EXPERIMENTAL): 300 IR grass pollen allergen extract tablet
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient at least 12 years of age. Female subjects of childbearing potential must have a negative urine pregnancy test result at baseline and practice a reliable method of contraception throughout the study.~* Mild to moderate facial acne vulgaris~* Able to understand the requirements of the study and sign informed consent/HIPAA authorization forms. Subjects under the legal age of consent in the state where the study is conducted must also have the written, informed consent of a parent or legal guardian.~Exclusion Criteria:~* Female subjects who are pregnant (positive urine pregnancy test), breast feeding or who are of childbearing potential and not practicing a reliable method of birth control~* Allergy or sensitivity to any component of the test medication~* Known hypersensitivity to to any component of the investigational formulations~* Known history of enteritis (regional enteritis, ulcerative colitis, pseudomembranous colitis, or antibiotic-associated colitis~* Beards or sideburns~* Skin disease/disorder that might interfere with the diagnosis or evaluation of acne vulgaris~* Evidence of recent alcohol or drug abuse~* Participation in an investigational drug study within 30 days of the baseline visit

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duac gel (Type: ACTIVE_COMPARATOR): Clindamycin and benzoyl peroxide gel
- Ziana gel (Type: ACTIVE_COMPARATOR): Clindamycin and tretinoin gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High risk for delirium age \> 65 history of delirium medical comorbidities ability to give informed consent~Exclusion Criteria:~* Dementia Alcohol abuse Current use of an antipsychotic Allergy to olanzapine

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be diagnosed with Pathological Gambling according to DSMIV criteria~* Subject must have at least 2 episodes of gambling behavior within the previous 2 weeks before screening~* Subject must have gambling urges of at least moderate intensity~Exclusion Criteria:~* Subjects must not have unstable medical illness or clinically significant abnormalities on lab tests, ECG, or physical exam~* Subjects with major depressive episode within the last 2 years~* Subjects with a history of attempted suicide~* Subjects with first degree relative with major depressive episode that resulted in hospitalization, attempted or completed suicide~* Subjects with a history of epilepsy or seizures~* Subjects with a myocardial infarction (heart attack) with in the last 6 months~* Subjects with a lifetime history of bipolar disorder, dementia, schizophrenia, or any psychotic disorder~* Subjects with current of recent DSM-IV diagnosis of substance abuse or dependence (with the exception of nicotine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ecopipam (Type: EXPERIMENTAL): Ecopipam is a selective antagonist of one the classes of dopamine receptor.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given first week of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Two Different Types of Ankle Foot Orthoses on Gait Outcomes in Patients With Subacute Stroke.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with first time unilateral stroke~* 4 - 20 weeks post-stroke onset~* resulting in hemiparesis with foot drop~Exclusion Criteria:~* Inability to receive a double adjustable AFO through their insurance~* unable to follow two steps commands~* unable to ambulate 20 feet with or without assistive device with a minimum level of assistance of contact guard assistance~* diagnosis of cerebellar stroke~* non ambulatory prior to stroke onset

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PLS AFO first then DA AFO (Type: EXPERIMENTAL): Participants will be assigned to practice with Posterior Leaf spring AFO for a week, then they will be assigned to practice with Double adjustable AFO for another week.
- DA AFO first then PLS AFO (Type: EXPERIMENTAL): Participants will be assigned to practice with Double adjustable AFO for a week, then they will be assigned to practice with Posterior Leaf spring AFO for another week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Two Formulations of Ixekizumab in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are healthy male or female participants, with chronic stable medical problems, that in the investigator's opinion will not place the subject at increased risk by participating in the study~Exclusion Criteria:~* Have a significant history of, or current, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or hematologic disorders that in the opinion of the investigator poses an unacceptable risk to the participant if participating in the study~* Are allergic or hypersensitive to the study medicine~* Had a vaccination with a live vaccine within 12 months prior to the first check-in or intend to get a vaccine for tuberculosis within 12 months of completing treatment on this study~* Have any type of hepatitis, human immunodeficiency virus (HIV) infection, or other serious infection~* Show evidence of active or latent tuberculosis (TB)~* Presence of significant neuropsychiatric disorder or a recent history of depression~* Have had any active or recent infection within 4 weeks of Day 1 that, in the opinion of the investigator, would pose an unacceptable risk to the participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Ixekizumab (Reference) (Type: EXPERIMENTAL): Approved formulation of 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection via autoinjector (AI).
- Ixekizumab (Test) (Type: EXPERIMENTAL): Test formulation of 80 mg ixekizumab administered as a SC injection via AI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adherence in Topical Treatment of Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Psoriasis patients aged 18-75 years with mild-moderate psoriasis. It is mandatory that patients have a smartphone and basic skills for use of the smartphone.~Exclusion Criteria:~* aged under 18 and above 75 years, guttate psoriasis, severe degree of psoriasis, i.e. pustular and erythrodermic psoriasis, lack of smartphone and user skills for the smartphone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- App as intervention + Enstilar© (Type: EXPERIMENTAL): Patients prescribed Calcipotriene + Betamethasone Dipropionatecutaneous foam receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation.
- Conventional instructions + Enstilar© (Type: NO_INTERVENTION): Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete